{"filing":{"accession_number":"0001178913-26-003690","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"zk2635763.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003690/zk2635763.htm"},"events":[{"id":21590,"run_id":19477,"accession_number":"0001178913-26-003690","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces the successful initiation of a Phase 2/3 clinical trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a transition from regulatory preparation into active clinical execution. This is a material operational and clinical milestone for a clinical-stage biotechnology company, but does not fit the specific named event types (earnings, executive changes, M\u0026A, impairment, etc.). The event is clearly operational/strategic in nature—a significant clinical development milestone—making operational_other the most appropriate classification.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":21266,"accession_number":"0001178913-26-003690","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces the successful initiation of a Phase 2/3 clinical trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a transition from regulatory preparation into active clinical execution. This is a material operational and clinical milestone for a clinical-stage biotechnology company, but does not fit the specific named event types (earnings, executive changes, M\u0026A, impairment, etc.). The event is clearly operational/strategic in nature—a significant clinical development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:08:25.818961+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21266,"accession_number":"0001178913-26-003690","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces the successful initiation of a Phase 2/3 clinical trial for SIL204 at Tel Aviv Sourasky Medical Center, marking a transition from regulatory preparation into active clinical execution. This is a material operational and clinical milestone for a clinical-stage biotechnology company, but does not fit the specific named event types (earnings, executive changes, M\u0026A, impairment, etc.). The event is clearly operational/strategic in nature—a significant clinical development milestone—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T20:08:25.818961+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-07-29"}]}